Clinical ResultsG1 Therapeutics announced the presentation of new positive Phase 2 results highlighting the positive impact of Cosela (trilaciclib) in combination with Trodelvy (sacituzumab govitecan) on overall survival (OS) and tolerability in metastatic triple negative breast cancer (mTNBC) patients.
EarningsThe company expects to have a sufficient cash runway to reach anticipated company profitability.
Licensing AgreementA global licensing agreement grants Deimos exclusive rights to develop, manufacture, and commercialize lerociclib for certain radioprotective uses in the U.S., Europe, Japan, and all other global markets, excluding the Asia-Pacific region.